NASDAQ:FATE Fate Therapeutics (FATE) Stock Price, News & Analysis $1.27 +0.02 (+1.60%) Closing price 02/13/2025 04:00 PM EasternExtended Trading$1.26 -0.01 (-0.39%) As of 02/13/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Fate Therapeutics Stock (NASDAQ:FATE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Fate Therapeutics alerts:Sign Up Key Stats Today's Range$1.24▼$1.2850-Day Range$1.21▼$2.7252-Week Range$1.04▼$8.83Volume1.51 million shsAverage Volume1.89 million shsMarket Capitalization$144.64 millionP/E RatioN/ADividend YieldN/APrice Target$6.75Consensus RatingHold Company OverviewFate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Read More… Fate Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks78th Percentile Overall ScoreFATE MarketRank™: Fate Therapeutics scored higher than 78% of companies evaluated by MarketBeat, and ranked 267th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingFate Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on 3 buy ratings, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageFate Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Fate Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Fate Therapeutics are expected to decrease in the coming year, from ($1.63) to ($1.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fate Therapeutics is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fate Therapeutics is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFate Therapeutics has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Fate Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.30% of the outstanding shares of Fate Therapeutics have been sold short.Short Interest Ratio / Days to CoverFate Therapeutics has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Fate Therapeutics has recently increased by 1.34%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFate Therapeutics does not currently pay a dividend.Dividend GrowthFate Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.70 Percentage of Shares Shorted11.30% of the outstanding shares of Fate Therapeutics have been sold short.Short Interest Ratio / Days to CoverFate Therapeutics has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Fate Therapeutics has recently increased by 1.34%, indicating that investor sentiment is decreasing. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for Fate Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 4 people have searched for FATE on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows5 people have added Fate Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Fate Therapeutics insiders have bought 2,848.53% more of their company's stock than they have sold. Specifically, they have bought $668,580.00 in company stock and sold $22,675.00 in company stock.Percentage Held by InsidersOnly 5.00% of the stock of Fate Therapeutics is held by insiders.Percentage Held by Institutions97.54% of the stock of Fate Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fate Therapeutics' insider trading history. Receive FATE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FATE Stock News HeadlinesFate Therapeutics, Inc. (NASDAQ:FATE) CEO Bahram Valamehr Sells 8,705 SharesJanuary 14, 2025 | insidertrades.comSpringworks Therapeutics (SWTX) Gets a Buy from BarclaysFebruary 11 at 9:44 AM | markets.businessinsider.com My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blueprint. And I have something surprising to tell you about it … It doesn't include Nvidia.February 14, 2025 | Weiss Ratings (Ad)Mersana Therapeutics (MRSN) Receives a Buy from TD CowenFebruary 10, 2025 | markets.businessinsider.comProtagonist Therapeutics (PTGX) Gets a Buy from TD CowenFebruary 8, 2025 | markets.businessinsider.comWe're Keeping An Eye On Fate Therapeutics' (NASDAQ:FATE) Cash Burn RateFebruary 5, 2025 | finance.yahoo.comFate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking CheapFebruary 4, 2025 | seekingalpha.comFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)February 4, 2025 | globenewswire.comSee More Headlines FATE Stock Analysis - Frequently Asked Questions How have FATE shares performed this year? Fate Therapeutics' stock was trading at $1.65 on January 1st, 2025. Since then, FATE shares have decreased by 23.0% and is now trading at $1.27. View the best growth stocks for 2025 here. How were Fate Therapeutics' earnings last quarter? Fate Therapeutics, Inc. (NASDAQ:FATE) issued its quarterly earnings data on Tuesday, November, 12th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.42) by $0.02. The biopharmaceutical company earned $3.07 million during the quarter, compared to analysts' expectations of $0.88 million. Fate Therapeutics had a negative net margin of 1,325.43% and a negative trailing twelve-month return on equity of 45.88%. Who are Fate Therapeutics' major shareholders? Fate Therapeutics' top institutional investors include Vanguard Group Inc. (9.07%), Geode Capital Management LLC (1.96%), JPMorgan Chase & Co. (1.47%) and Walleye Capital LLC (0.95%). Insiders that own company stock include Redmile Group, Llc, J Scott Wolchko, Bahram Valamehr, John Mendlein, Jerome Charles Bressi, Cindy Tahl, Yu-Waye Chu, Mark Plavsic, Edward J Dulac III, Brian T Powl and Yuan Xu. View institutional ownership trends. How do I buy shares of Fate Therapeutics? Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Fate Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fate Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Meta Platforms (META), Alibaba Group (BABA) and Netflix (NFLX). Company Calendar Last Earnings11/12/2024Today2/13/2025Next Earnings (Estimated)2/24/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:FATE CUSIPN/A CIK1434316 Webwww.fatetherapeutics.com Phone(858) 875-1800FaxN/AEmployees550Year FoundedN/APrice Target and Rating Average Stock Price Target$6.75 High Stock Price Target$10.00 Low Stock Price Target$5.00 Potential Upside/Downside+431.5%Consensus RatingHold Rating Score (0-4)2.30 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($1.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-160,930,000.00 Net Margins-1,325.43% Pretax Margin-1,325.43% Return on Equity-45.88% Return on Assets-33.95% Debt Debt-to-Equity RatioN/A Current Ratio8.29 Quick Ratio8.29 Sales & Book Value Annual Sales$63.53 million Price / Sales2.28 Cash FlowN/A Price / Cash FlowN/A Book Value$3.74 per share Price / Book0.34Miscellaneous Outstanding Shares113,890,000Free Float108,199,000Market Cap$144.64 million OptionableOptionable Beta2.02 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report This page (NASDAQ:FATE) was last updated on 2/14/2025 by MarketBeat.com Staff From Our Partners*Breaking News!* This Pharma NASDAQ Company and the U.S Army!!! This Little Known NASDAQ Company just released positive results from its drugs that have been undergoing testi...Trading Wire | SponsoredCentral Bank Abandons USDWarren Buffett Dumping Stocks at Record Levels… Discover how savvy Americans are positioning their retireme...True Gold Republic | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredJUST RELEASED: HUGE NEW A.I. TRADEI’ve traded every major tech boom since the dawn of the personal computer. And I can tell you one thing wit...The Oxford Club | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] But Will THIS Be His DownfallRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.